SCHEMBL18085055

SCHEMBL18085055

C=CCN1CCc2ccc(C)cc2C(c2ccccc2)C1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD1 P21728 11/20 0.73
▸ KDM4E B2RXH2 4/20 0.69
▸ MAPT P10636 4/20 0.69
▸ MTOR P42345 3/20 0.69
▸ CYP2D6 P10635 3/20 0.69
▸ THPO P40225 3/20 0.69
▸ HIF1A Q16665 3/20 0.69
▸ HSD17B10 Q99714 3/20 0.69
▸ TDP1 Q9NUW8 1/20 0.69
▸ LMNA P02545 3/20 0.68
▸ BLM P54132 3/20 0.68
▸ PMP22 Q01453 3/20 0.68
▸ DRD2 P14416 6/20 0.63
▸ CYP1A2 P05177 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ ALOX15 P16050 2/20 0.54
▸ NFKB1 P19838 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ GMNN O75496 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18085056 0.88 DRD1 (0.58) DRD1KDM4EMAPTMTORCYP2D6
SCHEMBL18085047 0.85 DRD1 (0.54) DRD1KDM4EMAPTMTORCYP2D6
SCHEMBL18064716 0.85 DRD1 (0.69) DRD1KDM4EMAPTMTORCYP2D6
SCHEMBL18085067 0.84 DRD1 (0.53) DRD1KDM4EMAPTMTORCYP2D6
SCHEMBL7390591 0.82 DRD1 (1.00) DRD1KDM4EMAPTMTORCYP2D6
Bromide SCHEMBL11288446 0.81 KDM4E (1.00) DRD1KDM4EMAPTMTORCYP2D6
Hydrochloric Acid SCHEMBL7203243 0.81 DRD1 (1.00) DRD1KDM4EMAPTMTORCYP2D6
SCHEMBL18085069 0.81 DRD1 (0.50) DRD1KDM4EMAPTMTORCYP2D6
SCHEMBL18085070 0.81 DRD1 (0.50) DRD1KDM4EMAPTMTORCYP2D6
SCHEMBL18085068 0.81 DRD1 (0.50) DRD1KDM4EMAPTMTORCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160272572-A1 ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN PURDUE RESEARCH FOUNDATION 2016-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272572-A1 ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN ADCY1, ADCY2, ADCY5 DRD1 3588/4885KDM4E 3215/4885MAPT 2563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback